Abstract
Furazabol, a new anabolic steroid, inhibited a rise in cholesterol levels in the serum and liver induced by cholesterol feeding, although its effects on phospholipids, triglycerides, and free fatty acids were not marked. Fatty acid compositions of serum esterified cholesterol and triglycerides were not so much affected by the furazabol treatment. Furazabol has been expected to possess the therapeutic effect on atherosclerosis, that is, the progression of atheromatous changes was significantly inhibited by the treatment with this compound. In addition, furazabol clearly lightened fatty degeneration of the liver.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
